Anticancer Drugs Olaparib Oncology Pharmacology Physiotherapy

Olaparib (Description-13)

In this article we will discuss Olaparib (Description-13)

In this article, we will discuss Olaparib (Description-13). So, let’s get started.

Patients with Renal Impairment
In a renal impairment trial, the mean AUC increased by 24% and Cmax by 15%, when olaparib was dosed in patients with mild renal impairment (CLcr=51-80 mL/min defined by the Cockcroft-Gault equation; n=13) and by 44% and 26%, respectively, when olaparib was dosed in patients with moderate renal
impairment (CLcr=31-50 mL/min; n=13), compared to those with normal renal function (CLcr ≥81 mL/min; n=12). There was no evidence of a relationship between the extent of plasma protein binding of olaparib and creatinine clearance. There are no data in patients with severe renal impairment or end-stage renal disease (CLcr ≤30 mL/min).

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.